OSLO, Norway, Oct. 19, 2022 /PRNewswire/ -- Hemispherian AS ("Hemispherian'' or the "Company"), a Norwegian preclinical pharmaceutical company focused on small molecule cancer therapeutics targeting the DNA damage response, is delighted to announce a successful European Innovation Council...